Vera Therapeutics Surges to 236th Most Traded Stock with 842% Volume Spike

On June 2, 2025, Vera Therapeutics (VERA) experienced a significant surge in trading volume, with a turnover of 3.99 billion, marking an 842.19% increase from the previous day. This substantial rise in trading activity positioned Vera as the 236th most traded stock of the day, reflecting a notable 67.49% increase in its stock price.

Vera Therapeutics announced that the ORIGIN Phase 3 trial for atacicept, a treatment for immunoglobulin A nephropathy (IgAN), successfully met its primary endpoint. Participants who received atacicept achieved a 46% reduction in proteinuria as measured by the 24-hour urine protein-to-creatinine ratio (UPCR) at week 36. This reduction was statistically significant and clinically meaningful, demonstrating a 42% superiority over the placebo group.

The positive results from the ORIGIN Phase 3 trial have positioned Vera Therapeutics to submit a Biologics License Application (BLA) to the FDA in the fourth quarter of 2025. This submission is crucial for the potential commercial launch of atacicept in 2026, which could significantly impact the standard of care for IgAN patients. The ongoing ORIGIN 3 trial is expected to complete in 2027, further evaluating the long-term effects of atacicept on kidney function.

Vera Therapeutics has also seen notable insider trading activity, with 15 sales transactions recorded in the past six months. Marshall Fordyce, the President and CEO, sold 72,188 shares, totaling approximately $2,852,651. This activity suggests that insiders may be taking profits from the recent stock price increase, which could be a signal for investors to monitor closely.

Institutional investors have shown mixed sentiment towards Vera Therapeutics. While some have increased their positions, others have significantly reduced theirs. For instance, Paradigm Biocapital Advisors LP removed all 1,437,339 shares from their portfolio, while Vestal Point Capital, LP added 1,425,000 shares, indicating a 132.6% increase in their holdings. These movements reflect the varying levels of confidence among institutional investors regarding Vera's future prospects.

Analysts have also weighed in on Vera Therapeutics, with Wolfe Research issuing an "Outperform" rating on February 4, 2025. This rating suggests that analysts are optimistic about the company's potential for growth, particularly in light of the positive results from the ORIGIN Phase 3 trial. However, investors should remain cautious, as the regulatory approval process and market competition could impact Vera's ability to achieve its goals.